Hormone Replacement Therapy in Post-Menopause Hormone-Dependent Gynecological Cancer Patients: A Narrative Review

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Apr 9

PMID 38592285

Authors

Paola Villa

Valentina Elisabetta Bounous

Inbal Dona Amar

Federica Bernardini

Margherita Giorgi

Daniela Attianese

Annamaria Ferrero

Marika DOria

Giovanni Scambia

Affiliations

Soon will be listed here.

Abstract

Background: Advances in the treatment of gynecological cancer have led to improvements in survival but also an increase in menopausal symptoms, especially in young women with premature iatrogenic menopause.

Methods: A narrative review was performed to clarify the possibility of prescribing hormone replacement therapy (HRT) after hormone-dependent gynecological cancers (ovarian cancer [OC], cervical adenocarcinoma [AC], and endometrial cancer [EC]).

Results: HRT can be prescribed to patients with early-stage, grade I-II OC who experience bothersome menopausal symptoms non-responsive to alternative non-hormone therapy after optimal surgery. Caution should be exercised in administering HRT after serous borderline tumors and endometrioid OC, and HRT is not recommended in low-grade serous OC. HRT is not contraindicated in AC survivors. After surgery for EC, HRT can be prescribed in women with early-stage low-grade EC. There is not enough data to give indications to patients with advanced EC.

Conclusions: HRT can be discussed with patients, evaluating the risks and benefits of hormone-dependent gynecological cancer. Counseling should be performed by gynecologic oncologists experienced in the management of these patients.

Citing Articles

Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers.

Gorman M, Shih K Curr Treat Options Oncol. 2025; .

PMID: 40042741 DOI: 10.1007/s11864-025-01298-5.

Mimicking women's endocrine milieu in mice for women's health-related studies.

Constantin C, Matvienko D, Laszlo C, Scabia V, Battista L, Binz P NPJ Womens Health. 2025; 3(1):13.

PMID: 39991042 PMC: 11845318. DOI: 10.1038/s44294-025-00060-4.

Menopause in gynecologic cancer survivors: evidence for decision-making.

da Silva A, Praca M, Lamaita R, Batista Candido E, Paiva L, Soares J Rev Bras Ginecol Obstet. 2025; 47.

PMID: 39926120 PMC: 11805534. DOI: 10.61622/rbgo/2025FPS1.

References

Angioli R, Luvero D, Armento G, Capriglione S, Plotti F, Scaletta G . Hormone replacement therapy in cancer survivors: Utopia?. Crit Rev Oncol Hematol. 2018; 124:51-60. DOI: 10.1016/j.critrevonc.2018.02.005. View

Ayhan A, Taskiran C, Simsek S, Sever A . Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?. Int J Gynecol Cancer. 2006; 16(2):805-8. DOI: 10.1111/j.1525-1438.2006.00526.x. View

Chapman J, Disaia P, Osann K, Roth P, Gillotte D, Berman M . Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol. 1996; 175(5):1195-200. DOI: 10.1016/s0002-9378(96)70027-3. View

Faubion S, Kuhle C, Shuster L, Rocca W . Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015; 18(4):483-91. PMC: 4581591. DOI: 10.3109/13697137.2015.1020484. View

Riggs B, Khosla S, Melton 3rd L . A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998; 13(5):763-73. DOI: 10.1359/jbmr.1998.13.5.763. View

Silverberg S, Bell D, Kurman R, Seidman J, Prat J, Ronnett B . Borderline ovarian tumors: key points and workshop summary. Hum Pathol. 2004; 35(8):910-7. DOI: 10.1016/j.humpath.2004.03.003. View

Bourdel N, Huchon C, Abdel Wahab C, Azais H, Bendifallah S, Bolze P . Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation. J Gynecol Obstet Hum Reprod. 2020; 50(1):101966. DOI: 10.1016/j.jogoh.2020.101966. View

Maxwell G, Tian C, Risinger J, Hamilton C, Barakat R . Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy?. Cancer. 2008; 113(6):1431-7. PMC: 4435958. DOI: 10.1002/cncr.23717. View

Eeles R, Tan S, Wiltshaw E, Fryatt I, AHern R, Shepherd J . Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ. 1991; 302(6771):259-62. PMC: 1668928. DOI: 10.1136/bmj.302.6771.259. View

10.

Brennan A, Hickey M . The use of menopausal hormone therapy after cancer. Best Pract Res Clin Obstet Gynaecol. 2021; 81:22-30. DOI: 10.1016/j.bpobgyn.2021.11.005. View

11.

DOronzo S, Stucci S, Tucci M, Silvestris F . Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev. 2015; 41(9):798-808. DOI: 10.1016/j.ctrv.2015.09.003. View

12.

Ursic-Vrscaj M, Bebar S, Zakelj M . Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause. 2001; 8(1):70-5. DOI: 10.1097/00042192-200101000-00012. View

13.

Gershenson D . Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol. 2016; 41:49-59. DOI: 10.1016/j.bpobgyn.2016.09.012. View

14.

Deli T, Orosz M, Jakab A . Hormone Replacement Therapy in Cancer Survivors - Review of the Literature. Pathol Oncol Res. 2019; 26(1):63-78. PMC: 7109141. DOI: 10.1007/s12253-018-00569-x. View

15.

Smith J, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M . Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003; 361(9364):1159-67. DOI: 10.1016/s0140-6736(03)12949-2. View

16.

Bartosch C, Monteiro-Reis S, Vieira R, Pereira A, Rodrigues M, Jeronimo C . Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors. PLoS One. 2015; 10(8):e0134969. PMC: 4529229. DOI: 10.1371/journal.pone.0134969. View

17.

Power L, Lefas G, Lambert P, Kim D, Evaniuk D, Lotocki R . Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival. Obstet Gynecol. 2016; 127(5):837-847. DOI: 10.1097/AOG.0000000000001396. View

18.

Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E . Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev. 2020; 1:CD012559. PMC: 7027384. DOI: 10.1002/14651858.CD012559.pub2. View

19.

Richardson A, Watson L, Persic M, Phillips A . Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma. Post Reprod Health. 2021; 27(3):167-173. DOI: 10.1177/20533691211028518. View

20.

Bryant G . Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma. South Med J. 1990; 83(6):725-6. DOI: 10.1097/00007611-199006000-00044. View